Skip to content
AnalystLens

Elevance Health, Inc. 8-K Report, Corporate Update (Oct 31, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed October 31, 2024
Period End
October 22, 2024
Security
ELV
In the record · 2016–202610-K1110-Q348-K133

ELV filed 11 annual reports (10-K), 34 quarterly reports (10-Q) and 133 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Deal closed8-K · Apr ’22Apr ’22
  3. Leadership change8-K · Feb ’26Feb ’26

01—Abstract

Summary

Summary of the 8-K filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.

Elevance Health, Inc. (ELV) has announced the successful closing of a significant notes offering, raising approximately $5.138 billiona in net proceeds.

This offering comprises multiple series of notes with varying interest rates and maturity dates, ranging from 2026 to 2064. The company intends to utilize these proceeds for general corporate purposes, including working capital, potential acquisitions, debt repayment, and share repurchases. This strategic move provides Elevance Health with substantial liquidity to fuel its growth initiatives and manage its capital structure.

Investors should note the diversified debt maturity profile and the stated uses of proceeds, which suggest a focus on both strategic growth and shareholder returns. The terms of the notes include provisions for redemption and a change of control clause that offers protection to noteholders under specific circumstances.

02—Key points

Key Highlights

  1. Elevance Health closed a notes offering totaling approximately $5.138 billion in net proceeds.
  2. The offering consists of six series of notes with maturities ranging from 2026 to 2064 and coupon rates from 4.500% to 5.850%.
  3. Proceeds are earmarked for general corporate purposes, including working capital, acquisitions, debt repayment, and stock repurchases.
  4. The company can redeem notes prior to maturity, subject to specific call provisions and associated premiums.
  5. A change of control provision, coupled with a credit rating downgrade, triggers a mandatory repurchase offer at 101% of principal for affected note series.
  6. The notes were registered under the Securities Act of 1933, indicating they are publicly offered securities.

03—Questions

Frequently Asked Questions

  1. What is the total amount raised from the notes offering?

    Elevance Health raised approximately $5.138 billion in net proceeds from the sale of the notes after deducting underwriting discounts and offering expenses.

  2. How does Elevance Health plan to use the proceeds from this offering?

    The company intends to use the net proceeds for working capital and general corporate purposes. This includes funding potential acquisitions, repaying short-term and long-term debt, and repurchasing its common stock under its share repurchase program.

  3. What are the key terms of the notes issued?

    Six series of notes were issued: 4.500% Notes due 2026, 4.750% Notes due 2030, 4.950% Notes due 2031, 5.200% Notes due 2035, 5.700% Notes due 2055, and 5.850% Notes due 2064. Interest payment schedules vary by series, and the company has the option to redeem notes under specific conditions.

  4. What happens if there is a change of control at Elevance Health?

    If a change of control event occurs and is accompanied by a downgrade of the notes' rating below investment grade by Moody's, S&P, and Fitch, Elevance Health will be required to make an offer to purchase all of the affected notes at 101% of their principal amount, plus accrued interest.

04—Continue

← View all 8-K filings